BENITIONSClinical Trial Intelligence

Predicting SSRI Efficacy in Veterans With PTSD

4期 提前终止 NCT04183205

适应症Posttraumatic Stress Disorder, Major Depressive Disorder
分期4期
申办方VA Office of Research and Development
状态提前终止
受试者人数19 人
干预(药物)LDAEP, sertraline
开始日期2019年9月11日
完成日期2025年3月30日
结果公布日2026年5月22日

摘要

This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the PZ Site) and Controlling for Baseline CAPS Score

CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale

Sertraline Arm10.8 ± 9.95 Scores on a scale
p-value.08
Slope3.13

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial as Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the CZ Site) and Controlling for Baseline CAPS Score

CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale

Sertraline Arm10.8 ± 9.95 Scores on a scale
p-value.01
Slope3.59

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial as Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the FZ Site) and Controlling for Baseline CAPS Score

CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale

Sertraline Arm10.8 ± 25.7 Scores on a scale
p-value.24
Slope2.24

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。